As of January 22, 2025, Monte Rosa Therapeutics (GLUE) has a market cap of $0.34 billion USD. According to our data, Monte Rosa Therapeutics is ranked No.6542 in global market value.
Year | Market Cap | %Change |
---|---|---|
Jan 22, 2025 | $0.34 B |
-20.32%
|
Dec 31, 2024 | $0.43 B |
22.83%
|
Dec 29, 2023 | $0.35 B |
-25.76%
|
Dec 30, 2022 | $0.47 B |
-62.73%
|
Dec 31, 2021 | $1.25 B |
100%
|
Name | Market Cap | Market cap difference | Regions |
---|---|---|---|
Arvinas
ARVN
|
$1.25 B |
0.000 M
|
USA
|
Kymera Therapeutics
KYMR
|
$2.86 B |
0.000 M
|
USA
|
C4 Therapeutics
CCCC
|
$0.26 B |
0.000 M
|
USA
|
Nurix Therapeutics
NRIX
|
$1.39 B |
0.000 M
|
USA
|
Relay Therapeutics
RLAY
|
$0.82 B |
0.000 M
|
USA
|
Revolution Medicines
RVMD
|
$7.56 B |
0.000 M
|
USA
|
Zentalis Pharmaceuticals
ZNTL
|
$0.16 B |
0.000 M
|
USA
|
Kronos Bio
KRON
|
$60.34 M |
0.000 M
|
USA
|
Tango Therapeutics
TNGX
|
$0.33 B |
-0.000 M
|
USA
|
Foghorn Therapeutics
FHTX
|
$0.24 B |
0.000 M
|
USA
|
Erasca
ERAS
|
$0.55 B |
-0.000 M
|
USA
|
Olema Pharmaceuticals
OLMA
|
$0.42 B |
0.000 M
|
USA
|
PMV Pharmaceuticals
PMVP
|
$68.31 M |
0.000 M
|
USA
|
Market Cap | = | GLUE Stock Price | * | GLUE Shares Outstanding |
= | $5.53 | * | 61.44 M | |
= | $0.34 B |